

Stereotaxis, Inc. (STXS)


NYSE: healthcare; SIC 3845, Electromedical & Electrotherapeutic Apparatus; CIK 0001289340

Stereotaxis, Inc. STXS; healthcare	
Grade	E A B C D E weakest fifth of 371 graded peers percentile 82.7; sampling error 2.5 points; lower is stronger
Rank	307 of 371
Profitability	C percentile 48.8
Solvency	D/E percentile 79.1
Growth and financing	C percentile 56.1
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$52.3M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	9 of 14
Graded from	filings received through Apr 3, 2026 189 days before the rescans; latest periodic filing 10-Q received Aug 12, 2026
Last close	\$1.11 2026-10-08; market equity \$111.7M
Price used in grade	None



E, the bear
weakest fifth of its sector;
letters are fifths of the 371
graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Apr 21, 2023, E from Mar 21, 2024, D/E from Apr 21, 2024

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

this report, "Stereotaxis", the "Company", "Registrant", "we", "us", and "our" refer to Stereotaxis, Inc. and its wholly owned subsidiaries. GenesisX RMN®, Genesis RMN®, Niobe®, Navigant®, Synchrony?, SynX?, Odyssey®, Odyssey Cinema?, MAGiC?, MAGiC Sweep?, EMAGIN?, Map-iT?, QuikCAS?, Cardiodrive®, Vdrive®, Vdrive Duo?, V-CAS?, V-Loop?, V-Sono?, and NuVizion? are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners. annual report on Form 10-K, including the sections entitled "Business" and "Management's Discussion and Analysis of

Financial Condition and Results of Operations," contains forward-looking statements.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 48.8						
Gross profitability		32.7%	32.2%	44.7	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(16.1%)	(6.6%)	27.3	811	2025-12-31
Gross margin stability, five years		5.9 pts	2.8 pts	74.4	243	2025-12-31
Solvency, sleeve percentile 79.1						
Twelve-month failure probability		0.21%	0.07%	71.3	248	2026-06-30
Altman Z double-prime		(37.38)	(0.31)	85.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		1.51x	2.96x	80.8	839	2025-12-31
Growth and financing, sleeve percentile 56.1						
Revenue growth, three-year compound		4.8%	10.0%	61.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		(0.7%)	2.1%	52.5	704	2025-12-31
Net share issuance, one year		13.1%	2.5%	54.8	634	2026-02-28

Among 371 peers

healthcare; letters are fifths of this list



Rank	Company	Percentile	Letter	Warnings
302	Hyperfine, Inc. (HYPR)	81.4	D/E	
303	Surgery Partners, Inc. (SGRY)	81.6	D/E	late filer
304	Personalis, Inc. (PSNL)	81.9	D/E	

305	Accuray Inc. (ARAY)	82.2	D/E	late filer
306	Moderna, Inc. (MRNA)	82.4	D/E	
307	Stereotaxis, Inc. (STXS) <	82.7	E	
308	SkinHealth Systems Inc. (SKIN)	83.0	E	
309	Karyopharm Therapeutics Inc. (KPTI)	83.2	E	dilution, distress, fortress balance sheet
310	Novavax Inc. (NVAX)	83.5	E	
311	Pyxis Oncology, Inc. (PYXS)	83.8	E	short runway, distress
312	Opko Health, Inc. (OPK)	84.1	E	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(53.7%)	8.0%	12
Distance from 52-week high	(68.9%)	(31.4%)	12
EBIT to enterprise value	(18.6%)	(1.5%)	24
Free cash flow yield	(12.4%)	(1.0%)	29
Book value to price	0.11	0.28	28
Sales to price	0.29	0.31	47
Composite equity issuance, five years	30.6%	20.3%	59
Relative strength against the sector, log excess return	(0.98)	(0.14)	12

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$10.5M
Operating cash flow, four quarters	-\$15.3M
Months of runway	8.2
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$819,845

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$17.1M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
2	assets	us-gaap:Assets	\$52.3M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
3	net income	us-gaap:NetIncomeLoss	-\$21.6M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$13.7M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
5	assets	us-gaap:Assets	\$46.7M	2024-12-31	2026-03-12	10-K	0001493152-26-009881
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$32.4M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
7	gross profit	us-gaap:GrossProfit	\$14.6M	2024-12-31	2026-03-12	10-K	0001493152-26-009881
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$26.9M	2024-12-31	2026-03-12	10-K	0001493152-26-009881

9	gross profit	us-gaap:GrossProfit	\$14.9M	2023-12-31	2025-03-14	10-K	0001493152-25-010352
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$26.8M	2023-12-31	2025-03-14	10-K	0001493152-25-010352
11	gross profit	us-gaap:GrossProfit	\$18.5M	2022-12-31	2024-03-08	10-K	0001493152-24-009371
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$28.1M	2022-12-31	2024-03-08	10-K	0001493152-24-009371
13	gross profit	us-gaap:GrossProfit	\$23.2M	2021-12-31	2023-03-09	10-K	0001493152-23-007106
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$35.0M	2021-12-31	2023-03-09	10-K	0001493152-23-007106
15	current assets	us-gaap:AssetsCurrent	\$33.8M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
16	current liabilities	us-gaap:LiabilitiesCurrent	\$22.4M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$583.4M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
18	operating income	us-gaap:OperatingIncomeLoss	-\$22.1M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
19	book equity	us-gaap:StockholdersEquity	\$13.5M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
20	liabilities	us-gaap:Liabilities	\$33.5M	2025-12-31	2026-03-12	10-K	0001493152-26-009881
21	total debt	us-gaap:LongTermDebt	\$18.4M	2015-12-31	2016-03-11	10-K	0001193125-16-501650
22	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.6M	2015-12-31	2018-03-20	10-K	0001193125-18-089265
23	operating income	us-gaap:OperatingIncomeLoss	-\$5.4M	2015-12-31	2017-03-16	10-K	0001193125-17-085191
24	depreciation amortization	us-gaap:Depreciation	\$320,301	2015-12-31	2017-03-16	10-K	0001193125-17-085191
25	operating income	us-gaap:OperatingIncomeLoss	-\$2.5M	2018-12-31	2020-03-16	10-K	0001493152-20-004012
26	interest expense	us-gaap:InterestExpense	\$16,566	2018-12-31	2019-03-15	10-K	0001493152-19-003425
27	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$93,000	2025-12-31	2026-03-12	10-K	0001493152-26-009881
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$8.5M	2024-12-31	2026-03-12	10-K	0001493152-26-009881
29	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$34,000	2024-12-31	2026-03-12	10-K	0001493152-26-009881
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.1M	2023-12-31	2025-03-14	10-K	0001493152-25-010352
31	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$366,000	2023-12-31	2025-03-14	10-K	0001493152-25-010352
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$8.4M	2022-12-31	2024-03-08	10-K	0001493152-24-009371
33	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$2.4M	2022-12-31	2024-03-08	10-K	0001493152-24-009371
34	assets	us-gaap:Assets	\$41.9M	2023-12-31	2025-03-14	10-K	0001493152-25-010352
35	assets	us-gaap:Assets	\$53.4M	2022-12-31	2024-03-08	10-K	0001493152-24-009371
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	97,248,936	2026-02-28	2026-04-03	10-K/A	0001493152-26-015172
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	85,979,662	2025-02-28	2025-03-14	10-K	0001493152-25-010352